New chemo combo shows promise for rare sarcoma
NCT ID NCT04605770
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing the combination of two chemotherapy drugs, pemetrexed and cisplatin, in 164 adults with advanced or recurrent soft tissue sarcoma. The goal is to see if this treatment can slow tumor growth in people who have already tried standard therapies. Participants will receive up to 6 cycles of the combination, followed by pemetrexed alone, and will be monitored for response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pemetrexed and cisplatin (chemotherapy drugs)
What this could lead to
If successful, this could provide a new chemotherapy option for people with advanced soft tissue sarcoma who have not responded to standard treatments.
What could go wrong
This is an early-phase trial with a small number of participants. The drugs may not work better than existing options, and side effects from chemotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA, SOFT TISSUE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance Hospital
RECRUITINGSeoul, 03722, South Korea
Contact Email: •••••@•••••